Should You Buy Johnson & Johnson Stock from the Philippines in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking the performance of Johnson & Johnson for over three years. Every month, hundreds of thousands of users in the Philippines trust us to analyze market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Johnson & Johnson.

What Is Johnson & Johnson?

The Johnson & Johnson Stock Price

The price of Johnson & Johnson stock is rising this week. As of the latest update, Johnson & Johnson is trading at $156.28, reflecting a 0.31% increase over the past 24 hours and a positive weekly gain of 0.49%. The company’s market capitalization stands at $376.02 billion, with an average daily volume of 6.05 million shares. Johnson & Johnson offers a P/E Ratio of 17.39, a solid dividend yield of 3.33%, and a low stock beta of 0.40. With its stable dividend and strong sector fundamentals, Johnson & Johnson offers reliable value and growth potential for investors in the Philippines.

Our full analysis of Johnson & Johnson stock

Drawing upon Johnson & Johnson’s latest financial disclosures and a rigorous review of its three-year stock performance, our analysis harnesses a blend of financial indicators, technical signals, sector market data, and peer benchmarking—processed through sophisticated in-house algorithms. This holistic perspective aims to identify value and emerging upside for quality-seeking investors in the healthcare and pharmaceutical sector. So, why might Johnson & Johnson stock once again become a strategic entry point into the global healthcare market in 2025?

Recent performance and market context

Johnson & Johnson (JNJ) is presently trading at $156.28, with a 0.31% increase in intraday value and a weekly gain of +0.49%. The share price has stayed resilient, maintaining a tight range between $140.68 and $169.99 over the past year, which reflects both market stability and defensive appeal—a particularly attractive feature in today’s global context. The company boasted an impressive market capitalization of $376.02 billion as of July 2025 and consistently strong trading volumes, confirming broad investor confidence. Recent positive developments include robust Q1 2025 results, a major acquisition in neuroscience (Intra-Cellular Therapies), new regulatory approvals (notably for TREMFYA in Crohn’s disease), and pipeline progress in key oncology candidates. Within a sector benefitting from demographic tailwinds, innovation-led demand, and government support worldwide—including in rapidly growing Southeast Asian markets like the Philippines—Johnson & Johnson offers rare resilience and expansion potential.

Technical analysis

From a technical perspective, signals are constructive. The Relative Strength Index (RSI) sits at 57.16, reflecting neutral momentum with slight upward bias—neither overbought nor oversold, so accumulation is supported. The MACD stands at 0.49, recently indicating a slight sell signal, but this is counterbalanced by bullish confirmation in other leading oscillators: Williams %R at -22.50 (suggesting accumulation) and CCI at 54.33 (neutral, but supportive). A strong cluster of moving averages—5-day ($155.71), 20-day ($154.02), 50-day ($153.27), and 200-day ($153.34)—are all issuing buy signals, with the 50-day average ($153.27) acting as solid technical support. The 52-week high at $169.99 forms a key resistance level and a likely price target should further positive catalysts emerge. Overall technical sentiment is rated “Strong Buy” by consensus, signaling promising potential for renewed upside legs in the months ahead.

Fundamental analysis

• Q1 2025 revenue reached $21.89 billion, a 2.4% year-on-year increase, reinforcing steady growth.
• Adjusted EPS hit $2.77 (+2.2%), surpassing analyst expectations.
• Net profit soared to $10.99 billion, a remarkable 237.9% leap versus Q1 2024, thanks to improved operating margins.
• The company’s current P/E ratio of 17.39 (with a forward P/E of 14.81) reflects a well-supported, attractive valuation for a blue-chip healthcare leader.
• Johnson & Johnson’s balance sheet remains robust with a diversified business, spanning innovative medicine and MedTech, both showing high single-digit growth.

What stands out most is the company’s status as a true “Dividend King”—with 63 years of consecutive increases and a current dividend yield of 3.33%—offering investors a rare blend of income stability and capital appreciation. Its brand strength, extensive IP portfolio, and global presence further cement its position as a low-volatility core holding, especially as an anchor in PH investors’ diversified portfolios.

Volume and liquidity

With an average daily trading volume of 6.05 million shares and an open float of 2.40 billion shares, Johnson & Johnson offers unmatched liquidity among global healthcare stocks. This high liquidity ensures frictionless trade execution and minimal slippage for both retail and institutional investors, making JNJ a stable and reliable option—even in volatile markets or during global macro shifts. The deep pool of market participants amplifies market confidence and fosters dynamic price discovery, allowing strategic positioning for both short-term momentum traders and long-term holders.

Catalysts and positive outlook

• Finalization of the Intra-Cellular Therapies acquisition, strengthening its neuroscience portfolio.
• Steady investment in the U.S. (over $55 billion committed) and expansion into high-growth international markets.
• Regulatory approvals and expected milestones for drugs in immunology (TREMFYA), oncology (RYBREVANT/LAZCLUZE), and medtech (OTTAVA surgical robotics).
• Ongoing digitalization of MedTech, including a new generation of AI-powered orthopedics and robotic interventions.
• Heightened focus on ESG, with sustainable supply chain innovation supporting Johnson & Johnson’s brand and global consumer preferences—something increasingly relevant for investors in the Philippines who value environmental responsibility.

Investment community sentiment remains overwhelmingly positive, with analysts assigning an $169.33 consensus price target (+8.35% upside). Management’s 2025 guidance is robust, calling for operating sales growth of 3.3–4.3% and adjusted EPS growth of up to 7.2%. As the global healthcare industry integrates technology deeper into drug discovery, patient engagement, and advanced diagnostics, Johnson & Johnson remains ideally positioned to translate these trends into lasting shareholder value.

Investment strategies

• Short-term: With the stock trading just above major support ($153.27), trend-following traders may consider opportunistic entries on pullbacks, targeting rebounds to the $169.99 resistance or on news-driven catalysts.
• Medium-term: Catalysts such as quarterly earnings beats, regulatory approvals, and dividend announcements offer timely entry points. The “Strong Buy” technical rating and upward momentum in operating results indicate attractive risk-reward.
• Long-term: For PH-based investors looking to compound wealth, the combination of predictable dividend growth, strong pipeline, world-class MedTech assets, and resilience to global cyclical risk make Johnson & Johnson a unique compounding engine.

A strategy of staged accumulation—building exposure on pullbacks, particularly near 50-day and 200-day moving averages—balances value orientation with upside capture well ahead of key company or sector events.

Is it the right time to buy Johnson & Johnson?

Synthesizing the evidence: Johnson & Johnson stands out for its consistent top-line growth, superior margin performance, world-class dividend history, and firm leadership in medical innovation and global healthcare delivery. Technical and fundamental tailwinds converge at present valuations—resulting in what seems to represent an excellent opportunity for investors seeking a balance of growth, stability, and reliable income.

Current technical support at $153.27 and robust analyst projections reinforce the sense that Johnson & Johnson may be entering a new bullish phase. While litigation and tariff risks remain to be monitored, the fundamentals and pipeline momentum justify renewed interest. For investors in the Philippines seeking global exposure, reliable returns, and participation in next-generation healthcare breakthroughs, Johnson & Johnson is a name to watch closely as the next wave of market leadership unfolds.

With a time-tested business model, a strong balance between defensive and growth attributes, and upcoming company-specific catalysts, Johnson & Johnson may well be among the most compelling long-term portfolio additions in today’s ever-evolving market landscape.

How to buy Johnson & Johnson stock in the Philippines?

Buying Johnson & Johnson stock online is accessible and secure through a regulated broker, allowing investors in the Philippines to participate in the global stock market. You can choose between two main methods: classic spot buying (cash purchase of shares to hold in your account) or trading via CFDs (contracts for difference), which lets you speculate with leverage on price changes without owning the shares. Both approaches can be executed 100% online, usually with just a few clicks. To choose your ideal provider, check out the broker comparison located further down this page.

Spot buying

Cash purchasing means buying Johnson & Johnson shares directly on the stock market and holding them in your name. For Philippine investors, brokers typically charge a fixed commission per order, usually between $2 and $7 (PHP equivalents may vary by platform). This method suits those seeking long-term growth and regular dividends.

Gain scenario

Suppose Johnson & Johnson shares are priced at $156.28 each. With a $1,000 stake, you can buy about 6 shares, after including a brokerage fee of around $5.

If the share price rises by 10%, your 6 shares become worth $1,100.

Result: +$100 gross gain, representing a solid 10% return.

Trading via CFD

CFD trading lets you bet on Johnson & Johnson’s share price gains or losses, using leverage to maximize your market exposure. Fees include the spread (difference between buy/sell price) and overnight charges if you hold your position for more than a day. CFDs are best for short- or medium-term investors comfortable with higher risk.

CFD Gain Scenario Example

You open a CFD on Johnson & Johnson using $1,000 and 5x leverage, meaning $5,000 in total exposure.

Gain scenario:
If the stock rises by 8%, your gain is 8% × 5 = 40%.
Result: +$400 profit on your $1,000 stake, excluding any fees.

Final advice

Before investing, always compare brokers’ fees, platform usability, and market access features. The best approach—spot buying for stability, or CFDs for short-term opportunity—depends on your investment profile, risk tolerance, and financial goals. A quick comparison table is available below to help you make the most informed choice.

Our 7 tips for buying Johnson & Johnson stock

The latest news about Johnson & Johnson

Johnson & Johnson’s stock price rose by 0.49% over the last seven days with stable trading volume. This moderate increase reflects ongoing investor confidence, supported by strong fundamentals and an established position in global healthcare. For investors in the Philippines, this performance highlights consistent value delivery, especially as the broader market remains volatile.

Recent analyst consensus sets the stock’s 12-month target at $169.33, with a positive sector outlook. Locking in an 8.35% potential upside, this projection is built on robust demand for Johnson & Johnson’s pharmaceutical and MedTech products, and ongoing innovation. Regional investors remain attentive to these fundamentals, especially given the company’s presence in many Southeast Asian healthcare supply chains.

Regulatory approval of TREMFYA for Crohn’s disease marks a recent boost to Johnson & Johnson’s innovative pipeline. This milestone, achieved days ago, opens new revenue streams for the company’s biopharmaceutical arm and demonstrates its capacity to meet unmet medical needs—a key consideration for Asian markets, where autoimmune conditions are on the rise.

Johnson & Johnson’s Q1 2025 results surpassed expectations with revenue growth and sharp net income increase. Recent quarterly revenue reached $21.89 billion (+2.4% vs. Q1 2024), beating analyst expectations and demonstrating resilience. Notably, net income surged by nearly 238%, underlining robust operational leverage. Such results reinforce the company’s reputation as a reliable global healthcare leader.

Dividend growth continues, with the quarterly payment raised to $1.30 per share, now yielding 3.33%. Long-term investors in the Philippines benefit from Johnson & Johnson’s stable and rising dividend stream, enhanced by its 63-year record of consecutive dividend hikes and strong cash-generation capacity. This makes the stock attractive for those seeking income and defensive exposure.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.